📰 Early Access Programs News
Page 2 - Early Access Programs News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Early Access Programs. Real-time updates on events, politics, business and more.
November 10, 2022
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results - read this article along with other careers information, tips and advice on BioSpace
October 31, 2022
DJ Biophytis publishes its key financial figures as at 30 June 2022, announces a restatement of the financial statements published as of December 31st, 2021 and provides an update on the oper Biophytis
October 31, 2022
Biophytis / Key word(s): Half Year ResultsBiophytis publishes its key financial figures as at 30 June 2022, announces a restatement of the financial statements published as of December 31st, 2021 and provides an update on the oper 31-Oct-2022 / 23:00 CET/CEST Biophytis publishes its key financial figures as at...
August 22, 2022
Jaguar Health Provides Company Updates and Reports 2022 Second Quarter Financials - read this article along with other careers information, tips and advice on BioSpace
May 16, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
May 13, 2022
Special Note Regarding Forward-Looking Statements Certain statements in this Report contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of... | May 13, 2022
May 10, 2022
Mytesi® net revenue of $2.6 million increased approximately 24% over the fourth quarter of 2021 and increased approximately 112% over Mytesi net revenue in the first quarter of 2021Core initiatives:OnTarget
March 11, 2022
Core 2022 development initiatives:Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD)Initiation and completion in 2H 2022
March 11, 2022
Press release content from Accesswire. The AP news staff was not involved in its creation.
May 10, 2021
Share this article Share this article WILLINGTON, England, May 10, 2021 /PRNewswire/ -- Bionical Emas, a global specialist Clinical Research Organization (CRO), has today announced the launch of a U.S. Expanded Access Program for Jazz Pharmaceuticals investigational therapy JZP458 (asparaginase Erwinia chrysanthemi (recombinant)) for the treatment of adult and pediatric patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) following hypersensitivity or silent inactiv...